We are live on ! Find out more
ACM

Aquilo Capital Management Portfolio holdings

AUM $55.8M
1-Year Est. Return 41.76%
This Fund
S&P 500
This Quarter Est. Return
-0.77%
1 Year Est. Return
-41.76%
3 Year Est. Return
-6.84%
5 Year Est. Return
+20.73%
10 Year Est. Return
–
AUM
$553M
AUM Growth
+$72.2M
Cap. Flow
+$97.5M
Cap. Flow %
17.62%
Top 10 Hldgs %
87.08%
Holding
19
New
2
Increased
11
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$31.2M
2
FDMT icon
4D Molecular Therapeutics
FDMT
+$12.4M
3
QURE icon
uniQure
QURE
+$9.08M
4
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$8.94M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$4.31M

Top Sells

Rank Stock Value
1
ANAB icon
AnaptysBio
ANAB
+$26.1M
2
SPRO icon
Spero Therapeutics
SPRO
+$1.81M

Sector Composition

Rank Sector Weight
1 Healthcare 58.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPY icon
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$810B
$119M 21.49%
+300,000
New +$116M
XBI icon
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$67.8M 12.26%
500,000
– –
SPRO icon
3
Spero Therapeutics
SPRO
$73M
$56.4M 10.19%
3,829,209
-103,000
-3% -$1.81M
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$43.6M 7.88%
1,705,392
+350,000
+26% +$8.94M
BPMC
5
DELISTED
Blueprint Medicines
BPMC
$41.1M 7.43%
423,012
+43,000
+11% +$4.29M
NGM
6
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$32.7M 5.91%
1,124,237
+118,703
+12% +$3.32M
HARP
7
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$32.5M 5.88%
+155,420
New +$31.2M
QURE icon
8
uniQure
QURE
$3.22B
$32.2M 5.82%
955,424
+253,374
+36% +$9.08M
DNTH icon
9
Dianthus Therapeutics
DNTH
$6.09B
$29.6M 5.35%
156,388
+14,737
+10% +$2.48M
ARWR icon
10
Arrowhead Research
ARWR
$12.4B
$27.1M 4.89%
407,926
+42,000
+11% +$3.26M
RGNX icon
11
Regenxbio
RGNX
$708M
$19.1M 3.45%
559,444
+56,000
+11% +$2.39M
FDMT icon
12
4D Molecular Therapeutics
FDMT
$562M
$13.1M 2.36%
300,886
+280,886
+1,404% +$12.4M
AMYT
13
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$11.1M 2.01%
800,000
– –
PVLA
14
Palvella Therapeutics
PVLA
$2.27B
$9.45M 1.71%
45,944
– –
LKFT
15
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$9M 1.63%
116,723
+46,734
+67% +$4.31M
ARGX icon
16
argenx
ARGX
$54.1B
$5.84M 1.06%
21,200
+8,500
+67% +$2.69M
GMAB icon
17
Genmab
GMAB
$19.5B
$3.94M 0.71%
120,000
+30,000
+33% +$1.13M
ANAB icon
18
AnaptysBio
ANAB
$1.68B
– –
-1,215,958
Closed -$26.1M
IBB icon
19
PUT
iShares Biotechnology ETF
IBB
$9.71B
– –
-500,000
Closed -$75.7M

Similar funds

VCM
VeriStar Capital Management New York $54.7M AUM 2.08% 1-Year Est. Return
YEPV
Yorktown Energy Partners VIII New York $52.9M AUM 30% 1-Year Est. Return
HWP
Heritage Wealth Partners Dublin, Ohio $65.6M AUM 16.69% 1-Year Est. Return
GIS
Grayhawk Investment Strategies Calgary, Alberta, Canada $43.9M AUM 6.23% 1-Year Est. Return
AA
AlphaQ Advisors Winter Park, Florida $41.7M AUM 12.96% 1-Year Est. Return
PGIM
Pacific Global Investment Management Glendale, California $70.7M AUM 14.46% 1-Year Est. Return
RGMC
Revolution Growth Management Company Washington, District of Columbia $70.8M AUM 20.1% 1-Year Est. Return
PAM
Pamalican Asset Management Hong Kong $75.4M AUM

Aquilo Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Aquilo Capital Management held 19 positions worth $553M, up 15% from $481M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Aquilo Capital Management deployed $97.5M of net new capital in Q1 2021, opening 2 new positions and adding to 11 existing holdings. Its largest new stake was Harpoon Therapeutics, Inc. Common Stock: 155,420 shares worth $32.5M.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 63% a quarter earlier.

On the sell side, the largest reduction was Spero Therapeutics, an estimated $1.81M trimmed.

  • Aquilo Capital Management's largest Q1 2021 buy was Harpoon Therapeutics, Inc. Common Stock: 155,420 shares worth $32.5M.
  • Aquilo Capital Management added most to 4D Molecular Therapeutics in Q1 2021, an estimated $12.4M increase.
  • Aquilo Capital Management's biggest Q1 2021 reduction was Spero Therapeutics, cutting an estimated $1.81M.
  • Aquilo Capital Management fully exited AnaptysBio in Q1 2021, selling an estimated $26.1M.
  • Aquilo Capital Management's ten largest holdings make up 87% of its $553M portfolio in Q1 2021.
  • Aquilo Capital Management opened 2 new positions and closed 2 in Q1 2021.
  • Aquilo Capital Management's portfolio value rose 15% quarter-over-quarter to $553M.

Based on Aquilo Capital Management's 13F filing for Q1 2021, filed 17 May 2021.